Recordati Deal History & Licensing Activity
Recordati is a specialty pharma headquartered in Italy. Over the past three years, Recordati has been involved in 2 licensing and acquisition transactions, with a primary focus on Oligonucleotides (2 deals). The company currently has 19 active clinical trials, primarily in Rare Disease.
Deals (12mo)
2
Active Trials
19
Top Modality
Oligonucleotides
Focus Area
Rare Disease
Recordati Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Recordati in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ZANVASTRO (zilganersen) | Ionis Pharmaceuticals, Inc. | Oligonucleotides | Approved | license | Jun 4, 2026 |
| mRNA-3927 | Moderna | mRNA | Phase 2 | collaboration | Jan 29, 2026 |
Recordati Pipeline Focus
Therapeutic areas and modalities where Recordati is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Recordati Strategic Signals
Key indicators of Recordati's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Recordati Clinical Pipeline
Recordati has 19 active clinical trials across 4 development phases.
3
Phase 4
9
Unknown
1
Phase 1
6
Phase 2
See How Your Asset Matches Recordati's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Recordati Licensing & Deal Activity
Recordati is a specialty pharma company based in Italy that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Recordati ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Recordati include Rare Disease (4 deals and trials), Hematological Malignancies (3 deals and trials), Metabolic (2 deals and trials), and Cardiovascular (1 deal and trial). In terms of modality, Recordati has shown particular interest in oligonucleotides, mrna.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Recordati and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Recordati's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.